CTOs on the Move

Montefiore St. Luke`s Cornwall

www.montefioreslc.org

 
Montefiore St. Luke`s Cornwall (MSLC) is a not-for-profit community hospital with campuses in Newburgh and Cornwall, NY. The hospital is dedicated to serving the health care needs of the Hudson Valley and has achieved excellence in the delivery of compassionate and comprehensive health care services. The Joint Commission noted MSLC for excellence in Key Quality Measures in the management of Heart Attack, Heart Failure, Stroke and Surgical Care. MSLC is also recognized as an industry leader in using information technology to improve patient care, by winning the Most Wired Award for the fourth year in a row. In January 2018, ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details

Similar Companies

Soap Buds

Soap Buds is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alliance for Science and Technology

Alliance for Science and Technology is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RamSoft

RamSoft, Inc. is a Rancho Cucamonga, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Novus Biologicals

Novus Biologicals is a Littleton, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Relmada

Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.